Top Markets
Coin of the day
Modalis Therapeutics Corporation Modalis Therapeutics Corporation

Modalis Therapeutics Corporation

4883
Classement en actions #29674
Modalis Therapeutics Corporation focuses on discovering and developing... Modalis Therapeutics Corporation focuses on discovering and developing treatments for severe genetic conditions. The company utilizes its proprietary CRISPR-GNDM technology to create therapies by controlling gene expression through the epigenetic modulation of specific genetic loci. Modalis also has a collaborative research agreement with JCR Pharmaceuticals Co., Ltd., aimed at assessing gene therapy drug delivery methods for the central nervous system (CNS), particularly for CNS-related disorders. Founded in 2016, the company was initially known as EdiGENE Corporation before changing its name to Modalis Therapeutics Corporation in August 2019. Its operations are based in Tokyo, Japan.
Prix de l'action
$0.20877985
Capitalisation boursière
$20.11M
Changement (1 jour)
-3.03%
Changement (1 an)
-66.13%
Pays
JP
Échange Modalis Therapeutics Corporation (4883)

Catégorie

Ratio P/B pour Modalis Therapeutics Corporation (4883)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Modalis Therapeutics Corporation, le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Modalis Therapeutics Corporation de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
- -
CH
- -
KR